1. Serum human epididymis protein 4 levels in colorectal cancer patients
   Yasemi̇n Kemal et al, 2017 CrossRef
2. Quantitative analysis of cell-free DNA in ovarian cancer
   XUEFENG SHAO et al, 2015 CrossRef
3. Comparison of Serum Human Epididymis Protein (HE4), Carbohydrate Antigen 125(CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) as Markers in Ovarian Cancer: A Systematic Review and a Meta-analysis
   Haniyeh Bashizadeh Fakhar et al, 2018, Indian J Gynecol Oncolog CrossRef
4. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies
   Hanyu Cao et al, 2018, Expert Review of Molecular Diagnostics CrossRef
5. HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect
   Duanyang Liu et al, 2018, J Ovarian Res CrossRef
6. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification
   Zvjezdana Špacir Prskalo et al, 2018, Journal of Obstetrics and Gynaecology CrossRef
7. Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes à visée diagnostique et pronostique devant une masse ovarienne suspecte d’un cancer épithélial. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l’égide du CNGOF et labellisée par l’INCa
   S. Bendifallah et al, 2019, Gynécologie Obstétrique Fertilité & Sénologie  CrossRef
8. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
   Vincent Dochez et al, 2019, J Ovarian Res CrossRef
9. Diagnostic performance of biomarkers for ovarian cancer
   Jinyong Hua et al, 2019, Medicine CrossRef
10. Endometriosis and Ovarian Cancer
    Sajal Gupta et al, 2015 CrossRef
11. Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer
    Ghazala Khan et al, 2015, Biomark�Cancer CrossRef
12. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass
    Elizabeth Lokich et al, 2015, Gynecologic Oncology CrossRef
13. BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer
    Liangxiang Su et al, 2015, Medicine CrossRef
14. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis
    Zhu Lan et al, 2016, Familial Cancer CrossRef
15. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women
    Yaping Tian et al, 2015, J Ovarian Res CrossRef
16. Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer
    Lei Zhang et al, 2016, Biomarkers CrossRef
17. Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer
    Lingli Hu et al, 2016, International Journal of Gynecological Cancer CrossRef
18. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses
    Amal Fawzy et al, 2016, Asian Pacific Journal of Cancer Prevention CrossRef
19. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma
    Kun Jiang et al, 2017, Applied Immunohistochemistry & Molecular Morphology CrossRef
20. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis
    Quan Zhou et al, 2016, PLoS ONE CrossRef
21. A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study
    Umut Riza Gündüz et al, 2016 CrossRef
22. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer
    Ying Shen et al, 2016, Tumor Biol. CrossRef
23. Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
    Vincent Dochez et al, 2019, JCM CrossRef
24. Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital
    Fatemeh Cheraghi et al, 2020, Iran South Med J CrossRef
25. Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer
    Huiqing Wang et al, 2017, Oncotarget CrossRef
26. Prediction of the treatment response in ovarian cancer: a ctDNA approach
    Mina Sharbatoghli et al, 2020, J Ovarian Res CrossRef
27. Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer
    Li Qiao et al, 2020 CrossRef
28. In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis
    Linlin Zhang et al, 2021, PLoS ONE CrossRef
29. Clinical analysis of 52 adolescent patients with ovarian masses ≥10 cm in diameter
    Bo Zhang et al, 2021, J Int Med Res CrossRef
30. Toward improvement of screening through mass spectrometry-based proteomics: Ovarian cancer as a case study
    Gordon T. Luu et al, 2021, International Journal of Mass Spectrometry CrossRef
31. Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
    Miguel Ángel Elorriaga et al, 2021, JPM CrossRef
32. Evaluation of Combined Cancer Markers With Lactate Dehydrogenase and Application of Machine Learning Algorithms for Differentiating Benign Disease From Malignant Ovarian Cancer
    Seri Jeong et al, 2021, Cancer Control CrossRef
33. Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
    Núria Carreras-Dieguez et al, 2022, Diagnostics CrossRef
34. The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies
    Ming-Li Sun et al, 2022, Front. Med. CrossRef
35. Biomarkers for Early Diagnosis of Ovarian Carcinoma
    G. Manasa et al, 2022, ACS Biomater. Sci. Eng. CrossRef
36. The Diagnostic Accuracy of Serum and Urine Human Epididymis Protein 4 (HE4) in Ovarian Cancer in 15,394 Subjects: An Updated Meta-Analysis.
    Neelam Nalini et al, 2022, Cureus CrossRef
37. Diagnostics of Ovarian Tumors in Postmenopausal Patients
    Chingis Mustafin et al, 2022, Diagnostics CrossRef
38. Diagnostic performance of CA125 , HE4 , ROMA, and CPH‐I in identifying primary ovarian cancer
    Hui‐Jing Luo et al, 2023, J of Obstet and Gynaecol CrossRef
39. Identification and Characterization of Aptamers Targeting Ovarian Cancer Biomarker Human Epididymis Protein 4 for the Application in Urine
    Antonija Hanžek et al, 2023, Cancers CrossRef
40. Fabrication of a Highly Sensitive Electrochemical Immunosensor for Human Epididymis Protein 4 (HE4) Detection
    Jian Qu et al, 2018, International Journal of Electrochemical Science CrossRef
41. Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer
    Masaya Uno et al, 2023, Obstet Gynecol Sci CrossRef
42. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker
    Hiroki Machida et al, 2023, Gynecol Obstet Invest CrossRef
43. Evaluation of artificial neural network and adaptive-network-based fuzzy inference system for ovarian and lung cancer prediction
    Semih Latif İPEK et al, 2024, J Health Sci Med /JHSM /jhsm CrossRef